{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FDA-approved+drug+or+combination+of+drugs",
    "query": {
      "intervention": "FDA-approved drug or combination of drugs"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 92,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FDA-approved+drug+or+combination+of+drugs&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T08:03:07.050Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04038502",
      "title": "Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castrate Resistant Prostate Cancer",
        "BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2",
        "RAD51B, RAD51C, RAD51D, or RAD54L Mutations"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 100,
      "start_date": "2019-10-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 18,
      "location_summary": "West Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04038502"
    },
    {
      "nct_id": "NCT06539637",
      "title": "Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "DHS Consulting",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-09-01",
      "completion_date": "2026-02",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 1,
      "location_summary": "Westbury, New York",
      "locations": [
        {
          "city": "Westbury",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06539637"
    },
    {
      "nct_id": "NCT01871506",
      "title": "Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Standard Care (SC)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Intensive Counseling (IC)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 303,
      "start_date": "2013-09",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01871506"
    },
    {
      "nct_id": "NCT01556425",
      "title": "The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "Vivitrol",
          "type": "DRUG"
        },
        {
          "name": "Employment-based opiate abstinence reinforcement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 84,
      "start_date": "2012-05",
      "completion_date": "2017-08-06",
      "has_results": true,
      "last_update_posted_date": "2018-03-12",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556425"
    },
    {
      "nct_id": "NCT04020185",
      "title": "Safety and Efficacy Study of IMSA101 in Refractory Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor (ICI)",
          "type": "DRUG"
        },
        {
          "name": "Immuno-oncology (IO) therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmuneSensor Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-09-23",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04020185"
    },
    {
      "nct_id": "NCT01933815",
      "title": "Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "TPI 287",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cortice Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2013-08",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2023-02-22",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri • Hackensack, New Jersey + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01933815"
    },
    {
      "nct_id": "NCT04141163",
      "title": "Metformin in Patients With Fragile X",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rowan University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2019-10-29",
      "completion_date": "2021-03",
      "has_results": false,
      "last_update_posted_date": "2019-10-31",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 1,
      "location_summary": "Stratford, New Jersey",
      "locations": [
        {
          "city": "Stratford",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04141163"
    },
    {
      "nct_id": "NCT04950660",
      "title": "Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Adolescent Idiopathic Scoliosis"
      ],
      "interventions": [
        {
          "name": "Caffeine Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Mercy Hospital Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 61,
      "start_date": "2019-12-11",
      "completion_date": "2024-08-01",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04950660"
    },
    {
      "nct_id": "NCT04786600",
      "title": "A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Signatera ctDNA assay",
          "type": "DEVICE"
        },
        {
          "name": "pre-specified sequence of FDA-approved drugs and drug combinations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 6,
      "start_date": "2022-03-14",
      "completion_date": "2024-03-19",
      "has_results": true,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04786600"
    },
    {
      "nct_id": "NCT05530694",
      "title": "Rheumatoid Arthritis Shared Decision Making",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Clinician communication training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient activation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "RA Medication summary guide and RA Choice",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2022-09-19",
      "completion_date": "2026-02-23",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-09T08:03:07.050Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Wilmington, Delaware • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05530694"
    }
  ]
}